OCT 22, 2020 7:00 AM PDT

Migraines: Dark Times and (Pharmaceutical) Rays of Hope

WRITTEN BY: Tara Fernandez


Despite being commonly used interchangeably, headaches and migraines are worlds apart. Migraines are by far much more prolonged and debilitating, encompassing a range of accompanying symptoms from throbbing pain and light sensitivity to nausea and vomiting. The pathophysiology of this condition is complex and identifying potential therapeutic targets has, for a long time, eluded neuroscientists. Among the challenges is that nobody knows what really causes migraines.

The current working theory is that the trigeminovascular system (a neural connection that innervates blood vessels in the head) is a major player. Recurrent activation and sensitization of this pathway alters the excitability of the brain, resulting in the hypersensitivity to light, sounds, and even smells. 

For the estimated 16 percent of the worldwide population that suffers from migraines, a silver lining has come in the form of a suite of migraine therapeutics that have recently entered the clinic. One of these is a migraine drug called erenumab (Aimovig) — a monoclonal antibody drug derived from natural immune systems. The antibody prevents both episodic as well as chronic migraines by blocking the activity of calcitonin gene-related peptide (CGRP), a potent peptide produced by neurons. Elevated levels of CGRP have been linked to a range of conditions including migraine, hypertension, and cardiac failure.

A recent study conducted by Australian scientists has highlighted the true potential of Erenumab at relieving severe migraine attacks in chronic sufferers. The study tracked migraine incidences in a cohort of almost 200 patients. After taking the drug, almost 60 percent of them had at least halved the number of migraines they experienced per month.

“These drugs represent a significant advance in migraine care, and with many patients describing them as ‘life-changing’, they bring new hope to many living with migraine disease,” said the study’s lead author Dr. Elspeth Hutton from Monash University.

Sources: Headache, AJMC, Nature.  


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
AUG 24, 2020
Immunology
Injectable Drug Stops HIV From Entering Cells
AUG 24, 2020
Injectable Drug Stops HIV From Entering Cells
Once in the body, HIV tracks down T cells that bear the CD4 receptor. It attaches to these immune cells, fusing itself w ...
SEP 07, 2020
Immunology
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
SEP 07, 2020
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
The ability to edit the human genome using CRISPR has been heralded as a revolution in medicine. However, one of the big ...
SEP 14, 2020
Microbiology
The Immune System Can Kill HIV with a Helper Molecule
SEP 14, 2020
The Immune System Can Kill HIV with a Helper Molecule
HIV attacks the human immune system's CD4 cells, a major player in the body's defense against pathogens.
SEP 15, 2020
Immunology
Common Spice Relieves Eye Inflammation in Dogs, Human Studies to Follow
SEP 15, 2020
Common Spice Relieves Eye Inflammation in Dogs, Human Studies to Follow
A therapeutic made from turmeric has been shown to help reduce the effects of a painful inflammatory eye condition in do ...
SEP 11, 2020
Immunology
Study Reveals Tumor Defense Mechanism... And How to Beat It
SEP 11, 2020
Study Reveals Tumor Defense Mechanism... And How to Beat It
  P53 is an infamous process gene at the core of the development of tumors.  When P53  functional, it pau ...
SEP 28, 2020
Genetics & Genomics
Why Some Young, Healthy People Get Severe COVID-19
SEP 28, 2020
Why Some Young, Healthy People Get Severe COVID-19
Since the start of the pandemic, scientists have been trying to find out why some people get such severe illness from SA ...
Loading Comments...